Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Explore linked clinical trials.20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT07435038 | |
| Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. | DDI (Drug-Drug Interaction) | Recruiting | Phase 1 | 2026-09-09 | NCT07809815 | |
| Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment | Hepatic Impairment (HI) | Recruiting | Phase 1 | 2026-09-09 | NCT07809802 | |
| Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants | DDI (Drug-Drug Interaction) | Recruiting | Phase 1 | 2026-09-09 | NCT07809789 | |
| Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-09-08 | NCT07806604 | |
| A Phase I Study of CFT8919 in Patients With Advanced NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-04 | NCT06641609 | |
| Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Not yet recruiting | Phase 4 | 2026-06-26 | NCT07671560 | |
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. | Solid Advanced Tumor | Recruiting | Phase 1 / Phase 2 | 2026-03-04 | NCT07448116 | |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, head and neck cancer, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT04930432 | |
| Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | non-small cell lung carcinoma | Recruiting | Phase 2 | 2025-09-30 | NCT07181499 | |
| X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | Brain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03753685 | |
| Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-03-20 | NCT06885840 | |
| A Study of BPI-460372 in Advanced Solid Tumor Patients | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-01-27 | NCT05789602 | |
| A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hepatocellular carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-small cell lung carcinoma | Recruiting | Phase 1 | 2025-01-27 | NCT05341557 | |
| A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor | Advanced Solid Cancer | Active, not recruiting | Phase 1 | 2025-01-27 | NCT03791112 | |
| Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-01-17 | NCT06780839 | |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2023-09-22 | NCT06041776 | |
| Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | Not yet recruiting | Phase 1 | 2023-08-29 | NCT06015568 | |
| A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2022-08-11 | NCT05498064 | |
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2022-01-11 | NCT05186506 |